We are monitoring the impact of COVID-19 on APAC Lung Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 836
Share on
Share on

Asia Pacific Lung Cancer Therapeutics Market Research Report - Segmented By Treatment Type & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends and Forecast (2019 - 2024)

Pulished: February, 2020
ID: 836
Pages: 141

APAC Lung Cancer Therapeutics Market Size & Growth (2019 - 2024)

The Asia-Pacific Lung Cancer Therapeutics Market was worth USD 1.09 billion in 2019 and estimated to be growing at a CAGR of 7.65%, to reach USD 1.58 billion by 2024.

Asia-Pacific countries such as India and China are the developing regions for the global lung cancer therapeutics market owing to the high occurrence of this disease along with growing healthcare alertness.

Lung cancer accounts for a greater share of the whole number of patients suffering from cancer. Small cell lung cancer type is dangerous due to the fact that there are no drugs present for its treatment and that the smaller size of cancer cells present in this type of cancer makes it harder to be treated even by surgical involvement.

The APAC lung cancer therapeutics market is expected to observe profitable growth in the coming years largely due to the stable increase in the occurrence of cancer cases. As the geriatric population is likely to increase, the incidence of lung cancer is predicted to rise, thus acting as a driver for revenue growth.

Lack of awareness among patients and side effects associated with the treatment therapies are expected to obstruct the growth of APAC lung cancer therapeutics market.

This research report segmented and sub-segmented into the following categories:

  • By Treatment Type: Chemotherapy (Cisplatin, Taxol, Navelbine, Camptosar and Alimta), Radiotherapy (External Beam, Internal Beam and Systemic) and Other Drugs (Abraxane, Avastin, Crizotinib, Docetaxel and Gefitinib)
  • By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC

Regionally, increasing the population base in countries like India and China is anticipated to increase the growth of this market in these areas.

The Top companies leading in the APAC Lung Cancer Therapeutics Market profiled in this report are Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmitKline, Eli Lilly and Company, Agennix AG, AstrazenecaPlc, and Sanofi-Aventis.

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

5. Market Segmentation                                                              

                5.1 By Treatment Type                                 

                                5.1.1 Chemotherapy                     

                                                5.1.1.1 Cisplatin

                                                5.1.1.2 Taxol      

                                                5.1.1.3 Navelbine            

                                                5.1.1.4 Camptosar          

                                                5.1.1.5 Alimta   

                                5.1.2 Radiotherapy                         

                                                5.1.2.1 External Beam   

                                                5.1.2.2 Internal Beam    

                                                5.1.2.3 Systemic              

                                5.1.3 Other Drugs                            

                                                5.1.3.1 Abraxane             

                                                5.1.3.2 Avastin 

                                                5.1.3.3 Crizotinib             

                                                5.1.3.4 Docetaxel            

                                                5.1.3.5 Gefitinib               

6. Geographical Analysis                                                              

                6.1 Introduction                                              

                6.2 China                                            

                6.3 India                                              

                6.4 Japan                                            

                6.5 South Korea                               

                6.6 Australia                                      

7. Pipeline Product Analysis                                                       

                7.1 Overview                                                    

                7.2 Pipeline Development Landscape                                                    

                7.3 Molecular Targets in the Pipeline                                                     

                7.4 Clinical Trials                                             

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target                       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                                  

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.                               

8. Strategic Analysis                                                       

                8.1 PESTLE analysis                                         

                                8.1.1 Political                     

                                8.1.2 Economic                 

                                8.1.3 Social                         

                                8.1.4 Technological                         

                                8.1.5 Legal                          

                                8.1.6 Environmental                      

                8.2 Porter’s Five analysis                                              

                                8.2.1 Bargaining Power of Suppliers                        

                                8.2.2 Bargaining Power of Consumers                    

                                8.2.3 Threat of New Entrants                     

                                8.2.4 Threat of Substitute Products and Services               

                                8.2.5 Competitive Rivalry within the Industry                      

9. Market Leaders' Analysis                                                        

                9.1 BoehringerIngelheim GmbH                               

                                9.1.1 Overview                

                                9.1.2 Product Analysis                   

                                9.1.3 Strategic Evaluation and Operations                            

                                9.1.4 Financial analysis                  

                                9.1.5 Legal issues                            

                                9.1.6 Recent Developments                       

                                9.1.7 SWOT analysis                       

                                9.1.8 Analyst View                          

                9.2 Hoffman-La Roche                                  

                9.3 Pfizer Inc.                                    

                9.4 GlaxoSmitKline                                         

                9.5 Eli Lilly and Company                                             

                9.6 AstrazenecaPlc                                         

                9.7 Sanofi-Aventis                                          

                9.8 Agennix AG                                

10. Competitive Landscape                                                         

                10.1 Market share analysis                                          

                10.2 Merger and Acquisition Analysis                                     

                10.3 Agreements, collaborations and Joint Ventures                                       

                10.4 New Product Launches                                       

11. Expert Opinions                                                        

                11.1 Market Outlook                                     

                11.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Lung Cancer Therapeutics Market By Region, From 2019-2024 (USD Billion)
  2. Asia-Pacific Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  3. Asia-Pacific Chemotherapy Market By Region, From 2019-2024 (USD Billion)
  4. Asia-Pacific Radiotherapy Market By Region, From 2019-2024 (USD Billion)
  5. Asia-Pacific Other Lung Cancer Therapeutic Drugs Market By Region, From 2019-2024 (USD Billion)
  6. China Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  7. India Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  8. Japan Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  9. South Korea Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  10. Australia Lung Cancer Therapeutics Market By Treatment Type, From 2019-2024 (USD Billion)
  11. Asia-Pacific Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  12. Asia-Pacific Cisplatin Market By Region, From 2019-2024 (USD Billion)
  13. Asia-Pacific Taxol Market By Region, From 2019-2024 (USD Billion)
  14. Asia-Pacific Navelbine Market By Region, From 2019-2024 (USD Billion)
  15. Asia-Pacific Camptosar Market By Region, From 2019-2024 (USD Billion)
  16. Asia-Pacific Alimta Market By Region, From 2019-2024 (USD Billion)
  17. China Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  18. India Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  19. Japan Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  20. South Korea Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  21. Australia Lung Cancer Chemotherapy Market By Drug Type, From 2019-2024 (USD Billion)
  22. Asia-Pacific Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  23. Asia-Pacific External Beam Market By Region, From 2019-2024 (USD Billion)
  24. Asia-Pacific Internal Beam Market By Region, From 2019-2024 (USD Billion)
  25. Asia-Pacific Systemic Market By Region, From 2019-2024 (USD Billion)
  26. China Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  27. India Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  28. Japan Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  29. South Korea Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  30. Australia Lung Cancer Radiotherapy Market By Type, From 2019-2024 (USD Billion)
  31. Asia-Pacific Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  32. Asia-Pacific Abraxane Market By Region, From 2019-2024 (USD Billion)
  33. Asia-Pacific Avastin Market By Region, From 2019-2024 (USD Billion)
  34. Asia-Pacific Crizotinib Market By Region, From 2019-2024 (USD Billion)
  35. Asia-Pacific Docetaxel Market By Region, From 2019-2024 (USD Billion)
  36. Asia-Pacific Gefitinib Market By Region, From 2019-2024 (USD Billion)
  37. China Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  38. India Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  39. Japan Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  40. South Korea Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)
  41. Australia Other Lung Cancer Therapeutic Drugs Market By Drug Type, From 2019-2024 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample